Vivani Medical files Form 10 for spin-off of Cortigent; expects Nasdaq listing in Q3 2025

Vivani Medical, Inc.

Cortigent files Form 10 to spin off from Vivani as independent Nasdaq company; completion expected Q3 2025.
Orion Visual Cortical Prosthesis completed Early Feasibility Study in March 2025; has FDA Breakthrough Device designation.
Cortigent advancing Stroke Recovery System to improve arm/hand movement recovery after stroke paralysis.
Vivani will focus solely on NanoPortal GLP-1 implants for chronic weight management and type 2 diabetes.
Spin-off requires final board approval, tax opinion, and SEC/Nasdaq clearance; shares distributed to Vivani stockholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.